Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company focused on the research, development, and commercialization of cannabinoid-based prescription medicines. Headquartered in Oxford, the company operates at the intersection of biotechnology and pharmaceuticals, with a key emphasis on novel treatments targeting pain and neurological disorders. Its drug development pipeline includes proprietary cannabinoid derivatives and natural phytocannabinoids that interact with the endocannabinoid system. Among its lead programs are OCT461201, designed to address peripheral neuropathies and irritable bowel syndrome, along with additional compounds in development for conditions such as trigeminal neuralgia, neuropathic pain, and solid tumor immunotherapy. By pursuing scientific innovation in cannabinoid therapeutics, Oxford Cannabinoid Technologies Holdings Plc aims to address unmet needs in pain management and other challenging medical conditions, contributing to advancements in the biopharmaceutical sector.